title: Enhanced production and gene expression of interleukin-5 in patients with bronchial asthma: possible management of atopic diseases by down-regulation of interleukin-5 gene transcription.
abstract: Interleukin (IL)-5 was produced in vitro by peripheral blood mononuclear cells (PBMCs) of mite-sensitive atopic patients upon challenge with specific allergen, while PBMCs of healthy controls produced essentially no IL-5. Stimuli delivered by the combination of phorbol ester (PMA) and CA2+ ionophore (ionomycin) induced marked IL-5 production by PBMCs obtained from atopic as well as nonatopic asthmatics. CD2- or CD4-bearing-cell depletion almost completely removed IL-5 production and gene transcription while CD8 depletion did not. These findings indicated that CD4+ T cells are the principal source of IL-5 in asthmatic PBMCs. The capacity of PBMCs of atopic asthmatics, nonatopic asthmatics and healthy controls to produce IL-2, IL-3, IL-4, interferon-gamma and granulocyte/macrophage-colony-stimulating factor was comparable among the three groups. FK506 suppressed IL-5 production and gene expression in vitro in a dose-dependent manner.
authors.affiliation: Department of Medicine and Physical Therapy, University of Tokyo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Okudaira
authors.forename: A
authors.initials: A
authors.lastname: Mori
authors.forename: M
authors.initials: M
authors.lastname: Suko
authors.forename: T
authors.initials: T
authors.lastname: Etoh
authors.forename: H
authors.initials: H
authors.lastname: Nakagawa
authors.forename: K
authors.initials: K
authors.lastname: Ito
mesh_terms: D000485:Allergens; D000818:Animals; D039741:Antigens, Dermatophagoides; D001249:Asthma / Q000235:genetics* / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000502:physiology; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology; D006023:Glycoproteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000096:biosynthesis / Q000235:genetics; D006969:Hypersensitivity, Immediate / Q000235:genetics / Q000628:therapy*; D007371:Interferon-gamma / Q000096:biosynthesis / Q000235:genetics; D015848:Interleukin-5 / Q000096:biosynthesis* / Q000235:genetics; D007378:Interleukins / Q000096:biosynthesis / Q000235:genetics; D015759:Ionomycin / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D008925:Mites / Q000276:immunology; D050778:NFATC Transcription Factors; D009687:Nuclear Proteins; D016559:Tacrolimus / Q000494:pharmacology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014157:Transcription Factors / Q000502:physiology; D014158:Transcription, Genetic / Q000187:drug effects*
chemical_list: D000485:Allergens; D039741:Antigens, Dermatophagoides; D004268:DNA-Binding Proteins; D006023:Glycoproteins; D015848:Interleukin-5; D007378:Interleukins; D050778:NFATC Transcription Factors; D009687:Nuclear Proteins; D014157:Transcription Factors; D015759:Ionomycin; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D013755:Tetradecanoylphorbol Acetate; D016559:Tacrolimus